+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety of omitting adjuvant whole breast radiation therapy WBRT in women with breast cancer who have no clinical lymph node involvement and have achieved a complete pathological response after neoadjuvant chemotherapy. This prospective, multi-center, single arm cohort study focuses on women with newly diagnosed T1-3 node negative breast cancer treated with breast conserving surgery and axillary staging. The study aims to observe breast tumor recurrence and survival outcomes over a median 5-year follow-up period. Participants will not receive the standard adjuvant WBRT after surgery. Instead, they will be closely monitored for any recurrence or progression of breast cancer. The study includes women who have undergone a minimum of eight weeks of neoadjuvant chemotherapy, breast conserving surgery with complete tumor bed excision, and axillary staging surgery. The absence of residual invasive or in situ cancer pathological complete response in the breast and lymph nodes is required for enrollment. During the study, participants will be followed regularly to assess ipsilateral breast tumor recurrence, local and regional recurrence, distant recurrence, disease-free survival, and overall survival. Any additional treatments received for recurrence such as repeat surgery, systemic therapy, or radiation will be documented. The total study duration extends up to five years from enrollment, with researchers evaluating tumor recurrence as the primary outcome at the median five-year mark.

Age: 50Years +FEMALE
27 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations